City Therapeutics
Sevda Lule is a highly experienced researcher in the field of pharmacology and neuroscience, currently serving as a Principal Scientist in In Vivo Pharmacology at City Therapeutics since May 2025. Prior to this role, Sevda held positions as Principal Scientist in Delivery Sciences and In Vivo Pharmacology at Arbor Biotechnologies and as a Senior Scientist in Discovery Research at Codiak BioSciences. Sevda's background includes significant contributions as a Postdoctoral Researcher at Harvard Medical School and Massachusetts General Hospital, specializing in molecular neurogenetics, and a tenure as a Research Scientist and Lab Manager at Hacettepe University. Educational qualifications include a PhD in Neuroscience, an MS in Molecular Biology, and a BS in Biology, all from Hacettepe University, complemented by postdoctoral training in Neuroscience at Harvard Medical School.
This person is not in any teams
This person is not in any offices
City Therapeutics
Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.